9,657 Shares in Morphic Holding, Inc. (NASDAQ:MORF) Purchased by Lexington Partners L.P.

Lexington Partners L.P. bought a new position in Morphic Holding, Inc. (NASDAQ:MORF) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,657 shares of the company’s stock, valued at approximately $554,000. Morphic comprises about 0.4% of Lexington Partners L.P.’s investment portfolio, making the stock its 6th largest holding.

Several other hedge funds also recently bought and sold shares of MORF. Osaic Holdings Inc. increased its holdings in shares of Morphic by 683.4% during the 2nd quarter. Osaic Holdings Inc. now owns 5,891 shares of the company’s stock valued at $338,000 after acquiring an additional 5,139 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its position in shares of Morphic by 20.5% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,663 shares of the company’s stock worth $95,000 after acquiring an additional 283 shares during the period. Great West Life Assurance Co. Can lifted its position in shares of Morphic by 12.2% in the 2nd quarter. Great West Life Assurance Co. Can now owns 15,013 shares of the company’s stock worth $867,000 after acquiring an additional 1,632 shares during the period. ProShare Advisors LLC lifted its position in shares of Morphic by 19.9% in the 2nd quarter. ProShare Advisors LLC now owns 6,921 shares of the company’s stock worth $397,000 after acquiring an additional 1,151 shares during the period. Finally, Profund Advisors LLC lifted its position in shares of Morphic by 112.0% in the 2nd quarter. Profund Advisors LLC now owns 23,692 shares of the company’s stock worth $1,358,000 after acquiring an additional 12,519 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Leerink Partnrs reiterated an “outperform” rating on shares of Morphic in a research report on Monday, October 16th. BTIG Research downgraded Morphic from a “buy” rating to a “neutral” rating in a research report on Monday, September 25th. BMO Capital Markets cut their target price on Morphic from $106.00 to $52.00 and set an “outperform” rating for the company in a research report on Thursday, September 28th. TheStreet cut Morphic from a “c-” rating to a “d+” rating in a report on Wednesday, August 9th. Finally, Stifel Nicolaus dropped their price target on Morphic from $61.00 to $33.00 and set a “hold” rating for the company in a report on Monday, September 25th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Morphic presently has an average rating of “Moderate Buy” and a consensus target price of $61.71.

Morphic Stock Up 2.0 %

Shares of Morphic stock traded up $0.47 during trading on Monday, reaching $23.87. 84,104 shares of the company were exchanged, compared to its average volume of 652,372. Morphic Holding, Inc. has a twelve month low of $19.34 and a twelve month high of $63.08. The business has a 50-day moving average price of $27.57 and a 200-day moving average price of $46.51. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -7.34 and a beta of 1.35.

Insiders Place Their Bets

In other news, CFO Marc Schegerin sold 20,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $54.34, for a total value of $1,086,800.00. Following the sale, the chief financial officer now directly owns 24,136 shares in the company, valued at $1,311,550.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Joseph P. Slattery bought 2,400 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average price of $20.60 per share, for a total transaction of $49,440.00. Following the completion of the acquisition, the director now owns 9,066 shares of the company’s stock, valued at approximately $186,759.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Marc Schegerin sold 20,000 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $54.34, for a total value of $1,086,800.00. Following the sale, the chief financial officer now owns 24,136 shares in the company, valued at approximately $1,311,550.24. The disclosure for this sale can be found here. Corporate insiders own 28.10% of the company’s stock.

Morphic Company Profile

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease.